Biodexa Pharmaceuticals (BDRX) Profit After Tax (2013 - 2025)

Biodexa Pharmaceuticals has reported Profit After Tax for 13 years, with the latest figure at $0.0 in Q2 2025.

• Quarterly Profit After Tax changed N/A year-over-year to $0.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$14.1 million (changed N/A YoY) and the FY2025 annual result came in at -$8.4 million, down 14.47% from the prior year.
• Profit After Tax eased to $0.0 in Q2 2025 per BDRX's latest filing, from $0.0 in the prior quarter.
• Over five years, Profit After Tax peaked at $0.0 in Q4 2024 and troughed at -$10.4 million in Q4 2022.
• A 5-year average of -$4.3 million and a median of -$4.7 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax sank 110280.69% in 2022, then surged 100.0% in 2024.
• Over 5 years, Profit After Tax stood at -$9436.1 in 2021, then tumbled by 110280.69% to -$10.4 million in 2022, then climbed by 10.81% to -$9.3 million in 2023, then jumped by 100.0% to $0.0 in 2024, then sank by 79.21% to $0.0 in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered $0.0, $0.0, and -$9.3 million for Q2 2025, Q4 2024, and Q4 2023 respectively.